Quote:Do you know at what point in the clinical process keytruda received a location agnostic but biomarker specific approval.
Keytruda received its first approval in cancer in September 2014. It received its first approval across multiple tumor types that were unresectable or metastatic MSI-H or dMMR solid tumors in March 2023. Clinicaltrials.gov lists 1,883 trials or studies in cancer for keytruda between those two dates.